NasdaqGS:NTRABiotechs
Natera (NTRA) Reports Positive Phase III Trial Results in Muscle-Invasive Bladder Cancer
Natera (NTRA) recently reported positive topline results from the IMvigor011 clinical trial, demonstrating significant improvements in disease-free and overall survival for patients, which may correlate with the company’s 16% share price rise over the past month. This announcement, paired with raised earnings guidance and the launch of the Fetal Focus NIPT, further supports the upbeat sentiment. Against a backdrop where major stock indices like the S&P 500 and Nasdaq have shown mixed...